MedTrace Logo

Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients

NCT02448342 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2017-12-29

No results posted yet for this study

Summary

Multi center, randomized controlled study, to determine if a significant decrease in the rate of heart failure re-hospitalizations occurs during a follow-up period when - ReDS guided treatment is used as an adjunct to standard of care.

Conditions

Interventions

DEVICE

Remote Dielectric Sensing (ReDS) Wearable System

The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.

Sponsors & Collaborators

  • Sensible Medical Innovations Ltd.

    lead INDUSTRY

Principal Investigators

  • William Abraham, MD · Ohio State University

  • Aharon (Ronnie) Abbo, MD · Sensible Medical Innovations Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448342 on ClinicalTrials.gov